<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572234</url>
  </required_header>
  <id_info>
    <org_study_id>260-07-FB</org_study_id>
    <nct_id>NCT00572234</nct_id>
  </id_info>
  <brief_title>Bupropion in the Treatment of Methamphetamine Dependence</brief_title>
  <official_title>Bupropion in the Treatment of Methamphetamine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Methamphetamine dependence is a significant drug use disorder in the Midwest. While a number
      of psychosocial and pharmacological treatments have been studied, no specific treatments for
      methamphetamine have been identified. This study is a collaborative pre-clinical and clinical
      partnership examining bupropion in the treatment of methamphetamine dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nearly 40% of adults seeking substance use disorders (SUD) treatment in Nebraska report
      methamphetamine is their drug of choice. In preliminary studies examining bupropion in
      methamphetamine use, it was well tolerated, reduced craving for methamphetamine and reduced
      methamphetamine related euphoria. Investigators at the University of Nebraska Medical Center
      and the University of Nebraska-Lincoln have initiated studies examining bupropion in animals
      and humans as a potential intervention in addictive disorders. Pre-clinical studies in the
      Co-Investigator's laboratory were the first to demonstrate the potential utility of bupropion
      as a pharmacotherapy for methamphetamine use disorders (MUD) while the Principal Investigator
      studied bupropion as a smoking cessation aid in alcoholics.

      The primary goal of this study is to establish an interdisciplinary and translational
      collaboration to test bupropion in persons in treatment for methamphetamine dependence and to
      inform pre-clinical studies so as to enhance their practical applicability to clinical
      settings. The pilot clinical study will examine the treatment effect and safety of a 12 week
      course of bupropion in persons with methamphetamine use disorder. Concurrently, we will
      examine the efficacy of bupropion on methamphetamine self-administration in animal models
      which better simulates clinical approaches.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2007</start_date>
  <completion_date type="Actual">May 20, 2011</completion_date>
  <primary_completion_date type="Actual">April 6, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence.</measure>
    <time_frame>Assessed Methamphetamine use at weeks 12 and 24, week 24 reported</time_frame>
    <description>The primary outcome measure was number of days methamphetamine use/week at weeks 12 and week 24.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Methamphetamine Use Disorder</condition>
  <arm_group>
    <arm_group_label>Receiving Bupropion SR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving bupropion SR 12 week course of bupropion SR 150 mg, BID (twice a day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment as Usual</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Not receiving bupropion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion SR</intervention_name>
    <description>12 week course of bupropion SR 150 mg, BID</description>
    <arm_group_label>Receiving Bupropion SR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient in the substance use disorder program at either the Omaha VA Medical Center or
             at Catholic Charities Campus for Hope

          -  diagnosis of methamphetamine dependence as well as presence or history of psychosis
             based on the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition
             (DSM-IV) criteria (not to include patients in full sustained remission)

          -  provide names, addresses, and phone numbers of at least two collateral informants who
             can provide information on their methamphetamine and other drug use during follow-up

          -  must sign an informed consent as approved by the UNMC Internal Review Board (IRB) and
             Catholic Charities Research Committee.

        Exclusion Criteria:

          -  a history of severe injury to their brain

          -  advanced cardiac, pulmonary, renal or liver disease

          -  predisposition to seizures

          -  history of bulimia or anorexia nervosa

          -  current diagnosis of major depressive disorder

          -  diagnosis or past history of panic disorders, schizophrenia, or bipolar affective
             disorder

          -  family history or childhood history of epilepsy or seizures

          -  history of strokes, brain tumors, or bleeding in the brain.

          -  used any psychoactive drug within one week of study entry (two weeks for MAO
             (monoamine oxidase) inhibitors or protriptyline, four weeks for fluoxetine)

          -  currently using any theophylline product (e.g. Theodur)

          -  used an investigational drug in any study within the past four weeks

          -  used a therapeutic course of bupropion SR for &gt; 1 week at any time in the past 12
             months or have been evaluated in previous studies examining bupropion SR at anytime

          -  If female, the participant must not be pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen M Grant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Omaha Veterans Affairs Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic Charities Campus for Hope</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omaha Veterans Affairs Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2007</study_first_posted>
  <results_first_submitted>September 13, 2018</results_first_submitted>
  <results_first_submitted_qc>July 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2019</results_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Kathleen Grant MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Methamphetamine</keyword>
  <keyword>Bupropion SR (Sustained Release)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment: August 31, 2007 - April 6, 2010 Recruitment from residential substance use disorder treatment programs in Omaha and Lincoln, Nebraska.</recruitment_details>
      <pre_assignment_details>Initially participants were assigned to one of two randomization pools: one group with and one group without psychoses. However as of January 30, 2009 no participants met criteria for randomization to the psychosis arm of the study and the protocol was changed to remove the psychosis randomization pool.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Receiving Bupropion (Sustain Release) SR</title>
          <description>receiving bupropion SR
bupropion SR: 12 week course of bupropion SR 150 mg, (twice a day) BID</description>
        </group>
        <group group_id="P2">
          <title>Treatment as Usual</title>
          <description>Not receiving bupropion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Receiving Bupropion SR</title>
          <description>receiving bupropion SR
bupropion SR: 12 week course of bupropion SR 150 mg, BID</description>
        </group>
        <group group_id="B2">
          <title>Treatment as Usual</title>
          <description>Not receiving bupropion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="10.9"/>
                    <measurement group_id="B2" value="34" spread="7.7"/>
                    <measurement group_id="B3" value="34" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence.</title>
        <description>The primary outcome measure was number of days methamphetamine use/week at weeks 12 and week 24.</description>
        <time_frame>Assessed Methamphetamine use at weeks 12 and 24, week 24 reported</time_frame>
        <population>Analyses were per protocol and based on number of participants enrolled in study who were not withdrawn from the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Receiving Bupropion SR</title>
            <description>receiving bupropion SR 12 week course of bupropion SR 150 mg, BID
bupropion SR: 12 week course of bupropion SR 150 mg, BID</description>
          </group>
          <group group_id="O2">
            <title>Treatment as Usual</title>
            <description>Not receiving bupropion</description>
          </group>
        </group_list>
        <measure>
          <title>Estimate the Treatment Effect of Bupropion for Methamphetamine (Meth) Dependence.</title>
          <description>The primary outcome measure was number of days methamphetamine use/week at weeks 12 and week 24.</description>
          <population>Analyses were per protocol and based on number of participants enrolled in study who were not withdrawn from the study.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="1.9"/>
                    <measurement group_id="O2" value="6.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Receiving Bupropion SR</title>
          <description>receiving bupropion SR
bupropion SR: 12 week course of bupropion SR 150 mg, BID</description>
        </group>
        <group group_id="E2">
          <title>Treatment as Usual</title>
          <description>Not receiving bupropion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kathleen Grant, M.D.</name_or_title>
      <organization>University of Nebraska Medical Center</organization>
      <phone>(402) 995-4347</phone>
      <email>kathleen.grant2@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

